439 results on '"Smith, Gale"'
Search Results
2. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
3. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
4. Author Correction: Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge
5. Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
6. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
7. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
8. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
9. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial
10. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
11. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
12. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
13. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial
14. Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2
15. Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge
16. Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate
17. XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants
18. NVX-CoV2373 ancestral and NVX-CoV2540 BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
19. Facilitating Technology Integration through Effective Professional Development: A Local School Model.
20. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
21. The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century
22. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes
23. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models
24. Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
25. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
26. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
27. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs
28. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge
29. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans
30. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets
31. Immunogenicity and safety of a 4thhomologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial
32. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
33. Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity
34. Diet Induced Obesity and Diabetes Enhance Mortality and Reduces Vaccine Efficacy for SARS-CoV-2
35. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
36. Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates
37. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
38. The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century.
39. Conceptualizing Practice through Dialogue among Professional Home Economists.
40. Toward an Ideal of the Person Educated in Home Economics: An Invitation to Dialogue.
41. Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine in Early-Stage HIV-1-Infected Volunteers
42. Evaluating the Use of Standardized Patients in Undergraduate Psychiatric Nursing Experiences
43. Modification and Secretion of Human Interleukin 2 Produced in Insect Cells by a Baculovirus Expression Vector
44. Enhanced Immunity to Human Immunodeficiency Virus (HIV) Envelope Elicited by a Combined Vaccine Regimen Consisting of Priming with a Vaccinia Recombinant Expressing HIV Envelope and Boosting with gp160 Protein
45. Induction of CD4$^+$ Human Cytolytic T Cells Specific for HIV-Infected Cells by a gp160 Subunit Vaccine
46. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
47. Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants
48. Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and Quadrivalent Seasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant
49. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
50. Proteosomes, Emulsomes, and Cholera Toxin B Improve Nasal Immunogenicity of Human Immunodeficiency Virus gpl60 in Mice: Induction of Serum, Intestinal, Vaginal, and Lung IgA and IgG
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.